NCT06073574Completed
CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
The CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 160 (actual)
- First submitted
- 4 Oct 2023
- Start date
- 31 Mar 2021
- Primary completion date
- 13 Mar 2026
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Diseases
- Amyloidosis
- NCT number
- NCT06073574
- EudraCT number
- 2019-002835-27
What you commit to
- Study type: Observational
- Participants enrolled: 160
- From 31 Mar 2021 to the primary completion date, 13 Mar 2026
- 11 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Weight or body girth exceeds the limits of the cardiac MRI machine specifications.
- Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.
Other
- Contraindication or sensitivity to MRI contrast agents
- Orthopnea of sufficient severity to preclude supine scanning at screening.
Who the study is looking for
- To participate in the ION-682884-CS2MRI sub-study, participants must meet all inclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Puerta de Hierro Coordinator of this site? Confirm its status | Majadahonda | Spain | Unknown status |
| Synexus Scotland Clinical Research Centre Coordinator of this site? Confirm its status | Bellshill | United Kingdom | Unknown status |
| Synexus Midlands Clinical Research Centre Coordinator of this site? Confirm its status | Birmingham | United Kingdom | Unknown status |
| Synexus - Wales Coordinator of this site? Confirm its status | Cardiff | United Kingdom | Unknown status |
| Richmond Pharmacology Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Royal Free London NHS Foundation Trust Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Synexus Manchester Clinical Research Centre Coordinator of this site? Confirm its status | Manchester | United Kingdom | Unknown status |
| Azienda Ospedaliero-Universitaria Careggi Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
| Azienda Ospedale Università di Padova Coordinator of this site? Confirm its status | Padova | Italy | Unknown status |
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Oregon Health and Science University Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.